Vito Carretta

1.7k total citations · 1 hit paper
21 papers, 1.3k citations indexed

About

Vito Carretta is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Vito Carretta has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hepatology, 14 papers in Epidemiology and 5 papers in Rheumatology. Recurrent topics in Vito Carretta's work include Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (12 papers) and Hepatitis B Virus Studies (10 papers). Vito Carretta is often cited by papers focused on Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (12 papers) and Hepatitis B Virus Studies (10 papers). Vito Carretta collaborates with scholars based in Italy, Brazil and United States. Vito Carretta's co-authors include Donato Bacca, Alessandra Mangia, Nicola Minerva, Angelo Andriulli, Rosanna Santoro, Gaetano Scotto, Mario Romano, F. Vinelli, Giovanni Ricci and Fulvio Spirito and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Vito Carretta

21 papers receiving 1.2k citations

Hit Papers

Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks i... 2005 2026 2012 2019 2005 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
    2005 608 citations Alessandra Mangia, Rosanna Santoro et al. New England Journal of Medicine profile →

Peers

Vito Carretta
Nicola Minerva Italy
Donato Bacca Italy
R. Soffredini Italy
Li‐Po Lee Taiwan
Joann Harvey United States
Michelle Martinot‐Peignoux France
Dessislava I. Dimitrova United States
David Bernstein United States
Mauro Annese Italy
Giovanni Squadrito Italy
Nicola Minerva Italy
Vito Carretta
Citations per year, relative to Vito Carretta Vito Carretta (= 1×) peers Nicola Minerva

Countries citing papers authored by Vito Carretta

Since Specialization
Citations

This map shows the geographic impact of Vito Carretta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vito Carretta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vito Carretta more than expected).

Fields of papers citing papers by Vito Carretta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vito Carretta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vito Carretta. The network helps show where Vito Carretta may publish in the future.

Co-authorship network of co-authors of Vito Carretta

This figure shows the co-authorship network connecting the top 25 collaborators of Vito Carretta. A scholar is included among the top collaborators of Vito Carretta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vito Carretta. Vito Carretta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Scotto, Gaetano, Orlando Armignacco, Giulio Starnini, et al.. (2016). Hepatitis C and immigration: a multicentre study.. PubMed. 24(3). 210–6. 3 indexed citations
2.
Mangia, Alessandra, Giovanni Cenderello, A. Orlandini, et al.. (2014). Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience. PLoS ONE. 9(10). e110284–e110284. 7 indexed citations
3.
Mottola, Leonardo, Giovanni Cenderello, Valeria Piazzolla, et al.. (2014). Interleukin‐28B genetic variants in untreated Italian HCV‐infected patients: a multicentre study. Liver International. 35(2). 482–488. 4 indexed citations
4.
Mangia, Alessandra, Rita Santoro, Leonardo Mottola, et al.. (2011). 1331 LACK OF ASSOCIATION BETWEEN IL28B VARIANTS AND HBSAG CLEARANCE AFTER INTERFERON TREATMENT. Journal of Hepatology. 54. S525–S525. 5 indexed citations
5.
Mangia, Alessandra, Giuseppe Montalto, Leonardo Mottola, et al.. (2010). Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. Journal of Hepatology. 53(6). 1000–1005. 18 indexed citations
6.
Mangia, Alessandra, Alexander Thompson, Rosanna Santoro, et al.. (2010). An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response. Gastroenterology. 139(3). 821–827.e1. 250 indexed citations
7.
Mangia, Alessandra, Olav Dalgård, Hans Verbaan, et al.. (2010). Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg‐interferon α‐2b and ribavirin. Alimentary Pharmacology & Therapeutics. 31(12). 1346–1353. 13 indexed citations
8.
Mangia, Alessandra, Olav Dalgård, Hans Verbaan, et al.. (2009). 630 RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B. Journal of Hepatology. 50. S232–S232. 2 indexed citations
9.
10.
Mangia, Alessandra, Donato Bacca, Raffaele Cozzolongo, et al.. (2008). 8 FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION. Journal of Hepatology. 48. S6–S6. 3 indexed citations
11.
Mangia, Alessandra, Nicola Minerva, Donato Bacca, et al.. (2007). Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 47(1). 43–50. 181 indexed citations
12.
Mangia, Anita, Donato Bacca, Vito Carretta, et al.. (2007). [7] IN PTS WHO CLEAR HCVRNA AT WEEK 12, SVR IS HIGHER AFTER 72 THAN AFTER 48 WEEKS TX: RESULTS OF A RANDOMIZED CONTROLLED TRIAL (RCT). Journal of Hepatology. 46. S6–S6. 2 indexed citations
13.
Mangia, Alessandra, Rosanna Santoro, Nicola Minerva, et al.. (2005). Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3. New England Journal of Medicine. 352(25). 2609–2617. 608 indexed citations breakdown →
14.
15.
Mangia, Alessandra, Giorgio Ricci, Mario Romano, et al.. (2004). 93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study. Journal of Hepatology. 40. 34–34. 6 indexed citations
16.
17.
Mangia, Alessandra, Rosanna Santoro, Gioacchino Leandro, et al.. (2002). High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. Journal of Hepatology. 37(1). 109–116. 17 indexed citations
18.
19.
Mangia, Alessandra, Nicola Minerva, Mauro Annese, et al.. (2001). A Randomized Trial of Amantadine and Interferon Versus Interferon Alone As Initial Treatment for Chronic Hepatitis C. Hepatology. 33(4). 989–993. 45 indexed citations
20.
Mangia, Alessandra, Mauro Annese, Vito Carretta, et al.. (2001). High sustained response rate after ribavirin + IFN retreatment of patients (PTS) who have failed a previous course of IFN with or without amantadine. Journal of Hepatology. 34. 133–134. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicola Minerva Breakdown of academic impact, for papers by Donato Bacca Breakdown of academic impact, for papers by R. Soffredini Breakdown of academic impact, for papers by Li‐Po Lee Breakdown of academic impact, for papers by Joann Harvey Breakdown of academic impact, for papers by Michelle Martinot‐Peignoux Breakdown of academic impact, for papers by Dessislava I. Dimitrova Breakdown of academic impact, for papers by David Bernstein Breakdown of academic impact, for papers by Mauro Annese Breakdown of academic impact, for papers by Giovanni Squadrito
Rankless by CCL
2026